This is a free sample of content from Stem Cells: From Biological Principles to Regenerative Medicine.
Click here for more information on how to buy the book.

Index

A

Activin, 118, 217
AD, *see* Alzheimer's disease
Age-related macular degeneration (AMD), 59–60, 62–64, 74
Aging
  alveolar epithelial stem cells, 169
  DNA damage and mutations, 152–153
Airway epithelia, *see also* Alveolar epithelial stem cells
  archetype cells and evolution, 110
  cells
    distribution of epithelial functions by cell type, 106–108
    ionocytes, 103, 105
    lineage relationships, 108–110
    multiciliated cells, 103
    neuroendocrine cells, 106
    tuft cells, 105–106
  overview, 101–104
ALS, *see* Amyotrophic lateral sclerosis
Alveolar epithelial stem cells
  activation by injury, 167
  anatomical compartments and microenvironments, 164–167
  AT2 cell
    aging and disease, 169
    fibroblast association, 167–168
    functional overview, 163–164, 167
    growth factors, 168–169
    lung cancer studies, 173
    proliferation restraint, 168
    repair signaling, 169–171
  prospects for study, 174
Alzheimer's disease (AD), induced pluripotent stem cell–derived neuron models, 6–7
AMD, *see* Age-related macular degeneration
Amyotrophic lateral sclerosis (ALS), induced pluripotent stem cell–derived neuron models, 6–7
Angiomotin, 207
ARX, 118
ASD, *see* Autism spectrum disorder
ASLX1, 150, 152
Autism spectrum disorder (ASD), induced pluripotent stem cell–derived neuron models, 7–9

B

BDNF, 238
Bestrophin, 60
β Cell, *see* Diabetes; Pancreas
Biomaterials
  cell fate manipulation
    biochemical factors
      controlled release from biomaterials, 91–92
      immobilization on biomaterials, 91
      reversible immobilization of biochemical clues, 92–93
    biochemically defined static biomaterials, 90–91
    reversible stiffening biomaterials, 89
    softening biomaterials, 87–88
    stiffening biomaterials, 88–89
    tunable mechanics of biomaterials, 86
    tunable stress-relaxation biomaterials, 90
  stem cell
    behavior detection, 93–94
    culture advances, 84–86
Bipolar disorder, induced pluripotent stem cell–derived neuron models, 7–9
BMP4, 171
BMP6, 20
BMP7, 21
BMPR1α, 172
Brain organoid
  assembled organoids, 26–27
  cell diversity and architecture, 23–26
  cell survival and maturation, 26
  circuit formation, 24–25
  historical perspective
    extracellular matrix gels, 19–20
    three-dimensional brain protocols, 19
  neuronal activity and maturation, 24
  overview, 16–17
  patterning
    heterogeneity–uniformity tradeoff, 22–23
    self-patterning, 20–21
    small molecules in organoid patterning, 21–22
  prospects for study, 28
  signaling center assembly, 27–28

C

CACNA1C, 9
Cancer

© 2020 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Stem Cells: From Biological Principles to Regenerative Medicine.
Click here for more information on how to buy the book.

Cancer (*Continued*)
alveolar epithelial stem cells in lung cancer, 173
initiation and somatic mutations, 151–152
lineage-tracing research, 190–192
stem cell imaging
maintenance by cancer stem cells, 261–263
progression, 260
tumor initiation, 259–261
CARM1, 210
CCL2, 170
CD45, 184
CD73, 73
CDKL5, 9
CDX2, 205
Cell fate, *see* Biomaterials; Preimplantation embryo; Multimodal single-cell analysis
CFTR, 105
CGD, *see* Chronic granulomatous disease
Chronic granulomatous disease (CGD), gene therapy, 35–36
COL7A1, 42–44, 47
COL17A1, 149
CRISPR/Cas9
multimodal single-cell analysis, 240
progenitor cell discovery, 192–194
skin disease gene editing
epidermolysis bullosa
dominant, 47
recessive, 47
epidermolytic ichthyosis, 48
limitations, 48
overview, 46–47
CTLA-4, 120
CXCL12, 282

D

Diabetes
regenerative therapies
hepatocyte reprogramming to β cells, 134–136
overview, 132
prospects, 136–138
reprogramming somatic cells to β cells, 132–134
type 1
β-cell development, 116–117
historical perspective, 116
overview, 115–116
stem cell therapy, 117–120
DIS2, 8
DISC1, 8
DKK-1, 68
DNA damage
model systems for spontaneous mutation in tissues, 154–156
mutation
aging, 152–153
cancer initiation and somatic mutations, 151–152
clonal expansion in blood and solid tissues, 150
diversity in somatic genomes, 149–150
mechanisms, 144–145
stem cell
persistent damage and decline, 153–154
protection
competition between cells and lineages, 147–149
DNA damage response and repair, 145–147
quiescence, 147
DNMT3A, 150, 152
DNMT3A/B, 212

E

EB, *see* Embryoid body; Epidermolysis bullosa
EC, *see* Endothelial cell
ECM, *see* Extracellular matrix
EGFR, 168–169, 173
Embryogenesis, *see* Preimplantation embryo
Embryoid body (EB), history of study, 17
Embryonic stem cell (ESC)
artificial embryo derivation, 216–217
history of study, 17
neural fate promotion, 17–19
properties
human, 217–218
mouse, 213–216
EMT, *see* Epithelial-to-mesenchymal transition
Endothelial cell (EC)
imaging of generation, 251
progenitor discovery
blood vessels, 184, 186
lymphatic vessels, 186–187
Enterocyte, 103
EOMES, 216
Epidermolysis bullosa (EB)
gene editing
dominant, 47
recessive, 47
gene therapy, 34–35, 37, 40–46
Epidermolytic ichthyosis, gene editing, 48
Epigenetics, preimplantation embryo, 210–213
Epithelia, *see* Airway epithelia; Intestinal epithelia
Epithelial-to-mesenchymal transition (EMT), 238–239
ESC, *see* Embryonic stem cell
ESRRB, 214, 216
ETS2, 216
Extracellular matrix (ECM)
decellularized matrix for culture, 84–85
stem cell niche, 84–85

© 2020 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Stem Cells: From Biological Principles to Regenerative Medicine.
Click here for more information on how to buy the book.

F

FGF, *see* Fibroblast growth factor
FGFR2, 171
Fibroblast growth factor (FGF), 278
  FGF2, 21
  FGF8, 21
  FGF10, 171
  FGF19, 21–22
Fli1, 235
FOXA2, 117
FOXI1, 105
FUS, 7

G

Gata1, 235
GATA3, 205, 216
GATA6, 216
GBX2, 214
GCG, 118
Gdf9, 239
GDNF, 271, 273, 278
Gene editing, *see* CRISPR/Cas9
Gene therapy, skin diseases, *see also specific diseases*
  epidermal stem cell targeting, 38–40
  overview, 34
  prospects, 49
  vectors
    herpes simplex virus, 37–38
    lentivirus, 36–37
    retrovirus, 35–36
Germ line stem cell (GSC), *Drosophila*, 280–281
GESTALT, 192
GFRα1, 271, 277–278
GSK3B, 6

H

Hair follicle, stem cells, 145–149, 187–188, 254, 259, 277–278, 281–282
Hematopoietic stem cell (HSC)
  imaging
    generation, 251
    regenerative processes, 257
  multimodal single-cell analysis, 237–238
  niche, 282
  progenitor discovery, 184–185
  quantitative modeling, 301–302
Hepatocyte growth factor (HGF), 169
Herpes simplex virus (HSV), gene therapy vector for skin, 37–38
HGF, *see* Hepatocyte growth factor
Hippo, 207–208
HLA-G, 120
HNF4a, 117
HPX, 23
HSC, *see* Hematopoietic stem cell
HSV, *see* Herpes simplex virus
Hydrogel, stem cell culture, 85

I

Idiopathic pulmonary fibrosis (IPF), 169
IGFR, 169
Induced pluripotent stem cell (iPSC)
  brain disorder modeling with derived neurons
    neurodegenerative disorders, 6–7
    neuropsychiatric disorders, 7–9
    overview, 1–3
    prospects for study, 9–10
    validity of model system, 3–6
  epidermal repair, 40
Inner cell mass, *see* Preimplantation embryo
Insulin, 21
Interfollicular epidermis (IFE), 276, 282, 299–301
Intestinal epithelia
  archetype cells and evolution, 110
  cells
    distribution of epithelial functions by cell type, 106–108
    enterocytes, 103
    enteroendocrine cells, 106
    lineage relationships, 108–110
    tuft cells, 105–106
  crypt stem cells, 281, 295–299
  overview, 101–104
  stem cells in regeneration, 188
Intravital microscopy (IVM)
  organogenesis, 251–253
  overview, 249–251
  stem cell imaging
    cancer
      maintenance by cancer stem cells, 261–263
      progression, 260
      tumor initiation, 259–261
    plasticity during tissue homeostasis, 253–257
    prospects, 264
    regenerative processes, 257–259
IPF, *see* Idiopathic pulmonary fibrosis
IPF1, 117
iPSC, *see* Induced pluripotent stem cell
IVM, *see* Intravital microscopy

K

KCC2, 24
Klf1, 235
KLF2, 214
KLF4, 214–215
KRAS, 263
KRT1, 48
KRT10, 48

© 2020 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Stem Cells: From Biological Principles to Regenerative Medicine.
Click here for more information on how to buy the book.

L
LAMA3, 41
LAMB3, 41–42
LAMC2, 41
LATS1/2, 207
LCA, *see* Leber congenital amaurosis
Leber congenital amaurosis (LCA), 70
LEKTI, 46
LincGET, 210–211, 213
LINE1, 149, 212–213
Lineage tracing, *see also* Multimodal single-cell analysis
  cancer research, 190–192
  historical perspective, 178–180
  progenitor cell discovery
    endothelial cell progenitors
      blood vessels, 184, 186
      lymphatic vessels, 186–187
    hematopoietic stem cell progenitors, 184–185
    overview, 177–178
    vascular smooth muscle cell progenitors, 187
  prospects, 192–195
  site-specific recombination systems, 180–182
Liver
  developmental relationship with pancreas, 127–132
  hepatocyte reprogramming to β cells, 134–136
  structure and function, 126–127
LOH, *see* Loss of heterozygosity
Loss of heterozygosity (LOH), 145, 149–150
LRAT, 60
Lung, *see* Alveolar epithelial stem cells

M
MAFA, 117
Mammary stem cell, 302–303
MCM4, 153
MCM6, 153
MECP2, 9
MERTK, 60
Mettl7a1, 238
Microglia, brain organoids, 26
MMP14, 168
Multimodal single-cell analysis
  molecular mechanism inference, 234–236
  molecular time inference, 239–241
  overview of techniques, 228–232
  prospects, 241–242
  pseudotime concept, 236–239
  single-cell map charting, 233–234
  single-cell state defining, 229, 233
Mutation, *see* DNA damage
MYC, 215–216

N
NANOG, 210
Neat1, 210–211
NEB, *see* Neuroepithelial body
NESTIN, 23
Netherton syndrome (NS), gene therapy, 46
Neuroepithelial body (NEB), 106
NF2, 207
NGN3, 117
NHEJ, *see* Nonhomologous end-joining
NKCC1, 24
NKX6.1, 117–118
Noggin, 68
Nonhomologous end-joining (NHEJ), 144, 146
NOTCH1, 150, 152
NS, *see* Netherton syndrome
NTRK2, 238

O
Obox6, 239
OCT4, 205, 215
OKT, *see* Optokinetic head tracking
Oligodendrocyte precursor cell (OPC), brain organoids, 25
OPC, *see* Oligodendrocyte precursor cell
Optokinetic head tracking (OKT), 72
Organoid, *see* Brain organoid

P
p53, 149, 151
Pancreas, *see also* Diabetes
  developmental relationship with pancreas, 127–132
  hepatocyte reprogramming to β cells, 134–136
  structure and function, 126–127
Parkinson's disease (PD), induced pluripotent stem cell–derived neuron models, 6–7
PAX4, 117
PAX6, 23
PD, *see* Parkinson's disease
PD-L1, 120
PDX1, 117–118
Photoreceptor cell transplantation, *see* Retinal degeneration
PNEC, *see* Pulmonary neuroendocrine cell
PPM1D, 152
PRDM14, 210
Preimplantation embryo
  cell difference origins
    epigenetic modifications and transcription factor binding, 210–211
    partitioning errors, 208, 210
    timing, 208
  cell fate commitment timing, 208–209
  embryonic stem cell properties in mice, 213–216
  first lineage decision, 205–208
  overview, 203, 205
  pluripotency regulation

© 2020 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Stem Cells: From Biological Principles to Regenerative Medicine.
Click here for more information on how to buy the book.

chromatin remodeling, 211
DNA methylation, 212
histone modifications, 211–212
retrotransposon activation, 212–213
timeline in mouse, 204
Proliferative vitreoretinopathy (PVR), 60
PTPRZ1, 23
Pulmonary neuroendocrine cell (PNEC), 106
PVR, *see* Proliferative vitreoretinopathy

R

RA, *see* Retinoic acid
Reaggregation, history of study, 16–17
Retinal degeneration
overview, 59–61
photoreceptor cell transplantation
clinical application, 72–74
donor-derived cell suspensions, 64–66
human PSC-derived neuroretinal cell suspensions, 67–69
mouse PSC-derived retinal cell suspensions, 66–67
rescuing end-stage degeneration, 69–71
retinal pigment epithelial transplantation
animal models, 60, 62
clinical studies of stem cell transplantation, 62–64
structure, 60
retinal sheet transplantation, 71–72
Retinoic acid (RA), 117, 271, 273, 290–291
RPE65, 60

S

Schizophrenia, induced pluripotent stem cell–derived neuron models, 7–9
SCID, *see* Severe combined immunodeficiency
SCNT, *see* Somatic cell nuclear transfer
Severe combined immunodeficiency (SCID), gene therapy, 35
SHH, 21, 27–28
Single-cell analysis, *see* Multimodal single-cell analysis
SMAD, 21
SOD1, 7
Somatic cell nuclear transfer (SCNT), 211, 215, 217
SOX2, 23, 205, 210, 215
Spermatogenesis, mouse
advantages as model system, 273, 275
overview, 269
spermatogenic stem cells
context dependence of function, 277
differential competence to extracellular signals, 278
dynamic heterogeneity, 277
identity and regulation, 271–273, 292
ligand competition, 278
motion, 277–278, 282–283
neural competition and clonal drift, 276–277
niche system unity and diversity, 279–280
open niche microenvironment, 273–274
population asymmetry, 275–276
prospects for study, 283
quantitative modeling, 291–293
Spi1, 235
SPINK5, 46

T

TARDP, 7
TBX3, 214
TDP-43, 7
TEAD4, 207
TEB, *see* Terminal end bud
Terminal end bud (TEB), 303
TET2, 150, 152
TET3, 212
TFAP2C, 216
TFCP2L1, 214
TGIF2, 136
Transit-amplifying cell, 108
Trophectoderm, *see* Preimplantation embryo

V

Vascular smooth muscle cell (VSMC), progenitor discovery, 187
VSMC, *see* Vascular smooth muscle cell

W

WAS, *see* Wiscott–Aldrich syndrome
Wiscott–Aldrich syndrome (WAS), gene therapy, 35
WNT, 169–171

Y

YAP1, 170, 207

Z

Zfp42, 239

© 2020 by Cold Spring Harbor Laboratory Press. All rights reserved.